M&A TRANSACTION · 2020
Pharmaceutical Strategies Group 340B Link acquired by Omnicell, Inc.
$225.0M· 6.40x revenue
Target
Pharmaceutical Strategies Group 340B Link
Acquirer
Omnicell, Inc.
Strategic buyer
Disclosed financials at time of acquisition
Revenue
$35.0M
EBITDA
—
Deal Value
$225.0M
EV/EBITDA
—
Context
This $225.0M acquisition of Pharmaceutical Strategies Group 340B Link by Omnicell, Inc. sits in the pharmacy sub-vertical. Omnicell, Inc. is acquiring as a strategic buyer; see how strategic acquirers typically price pharmacy businesses on our Pharmacy strategic buyer-pool page.
Source
Data sourced from SEC filings and press releases. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology
Value your own pharmacy
Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.
Compare your business to the Pharmaceutical Strategies Group 340B Link acquisition.